DE602006014821D1 - Ex-vivo-verfahren zur genzuführung - Google Patents

Ex-vivo-verfahren zur genzuführung

Info

Publication number
DE602006014821D1
DE602006014821D1 DE602006014821T DE602006014821T DE602006014821D1 DE 602006014821 D1 DE602006014821 D1 DE 602006014821D1 DE 602006014821 T DE602006014821 T DE 602006014821T DE 602006014821 T DE602006014821 T DE 602006014821T DE 602006014821 D1 DE602006014821 D1 DE 602006014821D1
Authority
DE
Germany
Prior art keywords
generation procedure
vivo generation
particles
magnetic means
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014821T
Other languages
English (en)
Inventor
Jon Dobson
Christopher D Batich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keele University
University of Florida
University of Florida Research Foundation Inc
Original Assignee
Keele University
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keele University, University of Florida, University of Florida Research Foundation Inc filed Critical Keele University
Publication of DE602006014821D1 publication Critical patent/DE602006014821D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602006014821T 2005-04-22 2006-04-21 Ex-vivo-verfahren zur genzuführung Active DE602006014821D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0508110.4A GB0508110D0 (en) 2005-04-22 2005-04-22 Gene delivery
PCT/GB2006/001477 WO2006111770A2 (en) 2005-04-22 2006-04-21 Gene delivery

Publications (1)

Publication Number Publication Date
DE602006014821D1 true DE602006014821D1 (de) 2010-07-22

Family

ID=34639915

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014821T Active DE602006014821D1 (de) 2005-04-22 2006-04-21 Ex-vivo-verfahren zur genzuführung

Country Status (11)

Country Link
US (2) US8232102B2 (de)
EP (1) EP1885450B1 (de)
JP (1) JP5167119B2 (de)
CN (1) CN101193681A (de)
AT (1) ATE470477T1 (de)
AU (1) AU2006238697B2 (de)
CA (1) CA2605533A1 (de)
DE (1) DE602006014821D1 (de)
ES (1) ES2345505T3 (de)
GB (1) GB0508110D0 (de)
WO (1) WO2006111770A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
WO2007133801A2 (en) * 2006-05-15 2007-11-22 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
GB0717582D0 (en) * 2007-09-10 2007-10-17 Univ Keele Magnetic transfection device
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9669200B2 (en) 2010-08-06 2017-06-06 Boston Scientific Scimed, Inc. Systems and methods for the treatment of pelvic disorders including magnetic particulates
US9180172B2 (en) 2010-12-15 2015-11-10 Ams Research Corporation Treatment of Peyronies disease
US8979797B2 (en) 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
CN102172410B (zh) * 2011-01-14 2013-08-07 华南理工大学 用于癌症诊断与治疗的靶向纳米粒传输系统的构建方法
US9884076B2 (en) 2012-06-05 2018-02-06 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
EP3800254A1 (de) * 2012-06-08 2021-04-07 Ethris GmbH Pulmonale verabreichung von mrns
US9828603B2 (en) 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9951374B2 (en) 2013-02-19 2018-04-24 Wisconsin Alumni Research Foundation Enhanced throughput mineral coatings for optimization of stem cell behavior
AU2015327812B2 (en) 2014-10-03 2021-04-15 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017123662A1 (en) 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2020171783A1 (en) * 2019-02-20 2020-08-27 Sabanci Üniversitesi Rotary magnetic actuation system
EP4292660A1 (de) * 2022-06-13 2023-12-20 Fortis GmbH System zur verabreichung eines wirkstoffs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652257A (en) * 1985-03-21 1987-03-24 The United States Of America As Represented By The Secretary Of The Navy Magnetically-localizable, polymerized lipid vesicles and method of disrupting same
WO1997004830A1 (en) * 1995-07-28 1997-02-13 Gray James R Use of a polarizing field to modify the efficacy of a bioactive agent
US6203487B1 (en) 1997-12-31 2001-03-20 Thomas Jefferson University Use of magnetic particles in the focal delivery of cells
WO2002000870A2 (en) * 2000-06-26 2002-01-03 Christian Plank Method for transfecting cells using a magnetic field
US6997863B2 (en) * 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
WO2003068953A1 (fr) 2002-02-12 2003-08-21 The Mollennium Laboratories Vibrateur de molecules
AU2003301251A1 (en) 2002-10-15 2004-05-04 Ferx Incorporated Magnetically guided particles for radiative therapies
EP1553176A4 (de) 2002-10-16 2008-10-01 Universal Bio Research Co Ltd Vorrichtung zur einführung von biologischem material, verfahren zur einführung von biologischem material und magnetischer träger zur einführung von biologischem material
US8001977B2 (en) 2005-04-08 2011-08-23 Nanobiomagnetics, Inc. Device for moving magnetic nanoparticles through tissue
JP2007516216A (ja) 2003-09-12 2007-06-21 バンクラプシー エステート オブ ファークス， インコーポレイテッド 生物学的に活性な因子の部位特異的送達のための、磁気成分および生体適合性ポリマーを含む磁気標的化可能な粒子

Also Published As

Publication number Publication date
AU2006238697B2 (en) 2011-12-08
JP5167119B2 (ja) 2013-03-21
EP1885450A2 (de) 2008-02-13
AU2006238697A1 (en) 2006-10-26
CN101193681A (zh) 2008-06-04
US20120288505A1 (en) 2012-11-15
EP1885450B1 (de) 2010-06-09
JP2008536907A (ja) 2008-09-11
GB0508110D0 (en) 2005-06-01
US20080286361A1 (en) 2008-11-20
WO2006111770A2 (en) 2006-10-26
US8232102B2 (en) 2012-07-31
ATE470477T1 (de) 2010-06-15
CA2605533A1 (en) 2006-10-26
ES2345505T3 (es) 2010-09-24
WO2006111770A3 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
DE602006014821D1 (de) Ex-vivo-verfahren zur genzuführung
PH12014502880A1 (en) Lyophilized therapeutic peptibody formulations
TW200806280A (en) Pharmaceutical compositions
HK1136847A1 (en) Targeted integration into the ppp1r12c locus
WO2009012176A3 (en) Methods and compositions for treating brain diseases
WO2012024526A3 (en) Conjugates, particles, compositions, and related methods
WO2011049958A3 (en) Modulation of gel temperature of poloxamer-containing formulations
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
WO2006127768A3 (en) Microscale micropatterned engineered in vitor tissue
TW200745109A (en) Pyrrolo-pyridine kinase modulators
MY167579A (en) Glycoconjugation processes and compositions
TR201900670T4 (tr) İnhalasyon için yöntem ve formülasyon.
CO6650414A2 (es) Grupos objetivos de receptro de complemento 2 mejorados
EA201290838A1 (ru) Конъюгаты пирролбензодиазепина направленного действия
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
CY1116482T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια ογκων, ινωσης, και πνευμονικης κυψελιδικης πρωτεϊνωσης
WO2010033771A3 (en) Modulators of hsp70/dnak function and methods of use thereof
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2010014949A3 (en) Compositions comprising hepatocyte-like cells and uses thereof
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer